Gono Takahisa, Matsuda Masayuki, Shimojima Yasuhiro, Kaneko Kazuma, Murata Hiroshi, Ikeda Shu-ichi
Department of Internal Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
J Clin Neurosci. 2007 Oct;14(10):997-1000. doi: 10.1016/j.jocn.2006.07.011. Epub 2007 Jul 31.
We report a patient with multiple sclerosis (MS) who developed subcutaneous nodules on the face, shoulders and extremities while being treated with interferon (IFN)-beta-1b. These nodules fluctuated in parallel with myelopathy, and were diagnosed as lupus erythematosus profundus (LEP) based on histopathological findings. The patient showed no relapse of either neurological symptoms or subcutaneous nodules after cessation of IFN-beta-1b. This agent can cause induration and necrosis in the sites of injection but also systemic skin lesions such as LEP ascribable to its immunomodulatory effects.
我们报告了一名患有多发性硬化症（MS）的患者，该患者在接受β-1b干扰素（IFN）治疗时，面部、肩部和四肢出现了皮下结节。这些结节与脊髓病平行波动，并根据组织病理学检查结果被诊断为深部红斑狼疮（LEP）。在停用β-1b干扰素后，该患者的神经症状和皮下结节均未复发。这种药物可导致注射部位出现硬结和坏死，还可引起全身性皮肤病变，如归因于其免疫调节作用的LEP。
